ORPHA:50839
Cat-scratch disease
Also known as: Bartonellosis due to Bartonella henselae infection
Publications
5,180
95th percentile
Trials
2
Interventional, condition-specific
Researchers
1,005
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Cat-scratch disease is a rare infectious disease, caused by the Gram-negative bacteria Bartonella henselae, that is transmitted to humans via a scratch or bite of an infected cat and that has a variable clinical presentation but that usually manifests with an erythematous papule at the site of inoculation followed by chronic regional lymphadenopathy. Clinical course is usually self-limiting but disseminated illness with high fever, , granulomatous osteolytic lesions, encephalitis, retinitis, and atypical pneumonia can also occur. Cat-scratch disease can atypically present as parinaud oculoglandular syndrome (unilateral conjunctivitis and preauricular lymphadenopathy).
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0005692
- MeSH:D002372
- UMLS:C0007361
- NCIT:C84620
Additional Mondo synonyms (3)
Cat-scratch fever · bartonellosis due to Bartonella henselae infection · benign lymphoreticulosis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
5,180 matched papers (1,690 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
2 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
5,180
5,180 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
5,180 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
1,690 in the last 10 years · high confidence · 95th percentile (publications denominator)
Phrase hits: 5,180 · MeSH hits: 78
Who's working on it?
1,005
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Giladi M6 papers · 2026
The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Papers in Europe PMC - 02Yakubovsky M6 papers · 2026
The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Papers in Europe PMC - 03Drummond MR5 papers · 2026
Universidade Estadual de Campinas , Laboratório de Pesquisa Aplicada em Dermatologia e Bartoneloses , Campinas , São Paulo , Brazil.
Papers in Europe PMC - 04Velho PENF5 papers · 2026
Universidade Estadual de Campinas , Laboratório de Pesquisa Aplicada em Dermatologia e Bartoneloses , Campinas , São Paulo , Brazil.
Papers in Europe PMC - 05Ephros M4 papers · 2026
Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Papers in Europe PMC - 06Gadoth A4 papers · 2026
The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Papers in Europe PMC - 07Paran Y4 papers · 2026
The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Papers in Europe PMC - 08Yahav D4 papers · 2026
The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Papers in Europe PMC - 09Ben-Ami R3 papers · 2026
Gray Faculty of Medical and Health Sciences, Tel Aviv University, Israel; Department of Infectious Diseases and Infection Control, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Papers in Europe PMC - 10Grisaru-Soen G3 papers · 2026
Gray Faculty of Medical and Health Sciences, Tel Aviv University, Israel; Pediatric Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Dana Children's Hospital, Tel Aviv, Israel.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
2
interventional trials for this specific condition
2 interventional trials matched this specific condition name; none in our sample are currently recruiting.
Data as of 27 July 2026
2 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 82.4th percentile).
high confidence · 82.4th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
2 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Cat-scratch disease" OR "Bartonellosis due to Bartonella henselae infection" OR "Cat-scratch fever" OR "benign lymphoreticulosis"
MeSH descriptor terms unioned into the query: Cat-Scratch Disease
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Cat-scratch disease" OR "Bartonellosis due to Bartonella henselae infection" OR "Cat-scratch fever" OR "benign lymphoreticulosis"
Interventional trials matched via: both (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 2 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T00:20:02.468Z